Bath Savings Trust Co Cuts Stock Position in Eli Lilly and Company (NYSE:LLY)

Bath Savings Trust Co trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 0.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,611 shares of the company’s stock after selling 130 shares during the period. Eli Lilly and Company comprises about 1.9% of Bath Savings Trust Co’s investment portfolio, making the stock its 18th biggest position. Bath Savings Trust Co’s holdings in Eli Lilly and Company were worth $19,146,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in LLY. Regal Investment Advisors LLC grew its holdings in Eli Lilly and Company by 41.3% during the 4th quarter. Regal Investment Advisors LLC now owns 4,808 shares of the company’s stock valued at $2,803,000 after buying an additional 1,405 shares in the last quarter. VitalStone Financial LLC boosted its position in shares of Eli Lilly and Company by 35.5% during the 4th quarter. VitalStone Financial LLC now owns 1,249 shares of the company’s stock valued at $728,000 after acquiring an additional 327 shares during the last quarter. Advanced Portfolio Management LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at $1,736,000. Visionary Wealth Advisors increased its position in Eli Lilly and Company by 2.7% in the fourth quarter. Visionary Wealth Advisors now owns 1,872 shares of the company’s stock worth $1,091,000 after purchasing an additional 49 shares during the last quarter. Finally, Bridgewater Associates LP raised its stake in Eli Lilly and Company by 412.5% during the fourth quarter. Bridgewater Associates LP now owns 317,586 shares of the company’s stock valued at $185,127,000 after purchasing an additional 255,619 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Up 1.3 %

Shares of NYSE LLY opened at $898.40 on Tuesday. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53. The business has a fifty day moving average price of $900.13 and a 200 day moving average price of $848.40. The stock has a market capitalization of $853.84 billion, a P/E ratio of 132.31, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Equities research analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the company. Citigroup initiated coverage on Eli Lilly and Company in a research report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price target for the company. Berenberg Bank lifted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, Truist Financial reiterated a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.